Genscript Biotech (1548.HK) Aktie Kurs

Genscript Biotech Kurs

HKEX·STÄNGD
3,63
​
Marknaden stängd

Intäkterna har vuxit med 25,0 % per år under de senaste 13 åren till 959,53 M USD. Vinst per aktie har vuxit med 41,7 % per år under de senaste 11 åren. Genscript Biotechs nettovinstmarginal ligger på −55,5 %, upp från −68,1 % för några år sedan. Genscript Biotech har för närvarande en direktavkastning på cirka 0,33 %. Utdelningsandelen är omkring 10 % av vinsten. Analytikernas mediankursmål är 2,53 USD, vilket är under nuvarande kurs med 30,2 %. Av 16 analytiker ger 15 köpråd — den samlade bedömningen är Köp.

Genscript Biotech aktiekurs

Hämta dessa data via Eulerpool API

100 000 anrop/mån gratis · inget kreditkort

Genscript Biotech affärsmodell och aktieanalys

GenScript Biotech Corp. är ett ledande bioteknikbolag grundat i Nanjing, Kina 2002. Huvudkontoret ligger idag i New Jersey, USA, och företaget verkar globalt.

Vanliga frågor om Genscript Biotech-aktien

The business model of Genscript Biotech Corp focuses on providing integrated solutions for life sciences research and drug discovery. The company offers a comprehensive range of products and services, including gene synthesis, protein expression, antibody development, and molecular diagnostics. Genscript Biotech Corp aims to accelerate biological research and development by providing high-quality and cost-effective solutions to scientists worldwide. Through its innovative technologies and expertise, the company has gained a strong reputation in the biotech industry. Genscript Biotech Corp continually strives to enhance its capabilities and expand its product portfolio to meet the evolving needs of the scientific community.

Genscript Biotech Corp is primarily active in the biotechnology industry.

The main competitors of Genscript Biotech Corp in the market are Thermo Fisher Scientific Inc., Eurofins Scientific SE, and Sartorius AG.

Genscript Biotech Corp is a leading biotechnology company with a rich history and background. Established in 2002, the company specializes in providing high-quality services and products in the field of life sciences research. Genscript is dedicated to enabling advancements in scientific discoveries and breakthroughs through its expertise in gene synthesis, custom protein production, antibody development, and many other gene-related services. With its state-of-the-art facilities and a global customer base, Genscript has become a trusted partner for researchers and pharmaceutical companies worldwide. The company's commitment to innovation and excellence has helped propel it to the forefront of the biotech industry, making Genscript Biotech Corp a reliable choice for investors seeking opportunities in this dynamic sector.

Genscript Biotech Corp has achieved several significant milestones. As a leading biotechnology company, Genscript has made remarkable strides in the field. Notably, the company successfully completed the genome synthesis of the E. coli bacterium in 2010, which was a groundbreaking achievement. In 2015, Genscript became the first Chinese biotech firm to be listed on the Hong Kong Stock Exchange, marking a significant milestone for the company. Moreover, Genscript has continuously expanded its portfolio of services and products, catering to various research areas and providing innovative solutions to the scientific community. With such achievements, Genscript Biotech Corp stands as a prominent player in the biotech industry.

Genscript Biotech Corp is primarily present in several countries and regions across the globe. The company has a strong foothold in China, where its headquarters are located. Additionally, Genscript Biotech Corp has a significant presence in the United States, with offices and operations spread across various states. The company has also established a strong international presence, with operations and collaborations in Europe, Asia, and other regions worldwide. With its global reach, Genscript Biotech Corp continues to expand its presence and deliver innovative solutions in the field of biotechnology.

Genscript Biotech Corp represents values of innovation, collaboration, and commitment to scientific advancement. With a strong corporate philosophy centered around providing quality products and services, Genscript strives to enhance the understanding and application of biotechnology worldwide. The company is dedicated to delivering cutting-edge research tools, custom solutions, and high-quality services to enable scientists and researchers in various fields. Genscript Biotech Corp aims to foster a culture of excellence, integrity, and customer-centricity, positioning itself as a global leader in the biotech industry.

Analytiker sätter för närvarande ett genomsnittligt riktkurs på 2,67 USD för Genscript Biotech-aktien (median: 2,53 USD), vilket innebär −26,2 % mot senaste kurs. Konsensus baseras på 16 analytikerbetyg.

16 analytiker betygsätter för närvarande Genscript Biotech-aktien: 15 rekommenderar köp, 1 behåll och 0 sälj. För 2026 väntar sig analytiker att Genscript Biotech genererar intäkter på 898,14 M USD och vinst per aktie på 0,00 USD.

Omräknat till aktuell växelkurs handlas Genscript Biotech-aktien till 3,30 EUR (3,63 USD).

Genscript Biotech-aktien (1548.HK) är noterad på 4 börser, bland annat: Hongkong (HKEX) (1548.HK), Frankfurt (G51.F), München (G51.MU).

GenScript Biotech Corp is a leading company in the biotech industry that specializes in the development and manufacture of high-quality biological products and services. The company offers a wide range of products and services, including DNA synthesis, protein production, antibody production, cell line development, and diagnostic tools. The company's divisions include proprietary products, manufacturing, and CRO (Contract Research Organization). Proprietary products contribute a large portion of the company's revenue and include various products such as CRISPR/Cas9 kits, DNA sequencing, protein analysis, and antibody services. GenScript Biotech's manufacturing business model is highly tailored to customer needs. It is based on critical procedures that incorporate proven expertise and patented technologies. The model includes a targeted approach to developing the necessary production processes, quality controls at every step of the manufacturing process, and support throughout the customer's entire lifecycle. An essential goal of the company is to support customers in every phase of the manufacturing process to ensure smooth and successful production. The Contract Research Organization (CRO) division of GenScript Biotech focuses on supporting customers in early stages of biological research or clinical trials. Through partnerships with the company, customers are supported through services such as protein engineering, cell line development, cell therapy, in vivo services, and pharmaceutical development. The company also offers a variety of diagnostic solutions and laboratory services. Examples include the development of cellular assays, reagent manufacturing, and DNA sequencing services. Overall, GenScript Biotech Corp is strongly focused on providing rapid and flexible service to its customers by offering a wide range of biopharmaceuticals, diagnostic tools, and laboratory services. The company has a global presence with offices in China, the USA, Europe, Japan, and Singapore. As a company that prioritizes innovation and quality, GenScript Biotech holds a strong position in the biotechnology market. With its various divisions and high-quality offering of products and services, the company provides its customers with a valuable partner to achieve their goals in biotechnology.

Omsättningen för förväntad Genscript Biotech är 898,14 M USD. Denna siffra baseras på aktuella finansiella data och återspeglar företagets affärsresultat.

Nettovinsterna för förväntad Genscript Biotech är 8,29 M USD. Nettovinsterna återspeglar företagets lönsamhet efter avdrag för alla utgifter.

Kurs-vinstkvoten (P/E) för Genscript Biotech är för närvarande 974,50. P/E-talet jämför den aktuella aktiekursen med vinsten per aktie och hjälper investerare att bedöma värderingen av Genscript Biotech-aktien.

Kurs-försäljningskvoten (P/S) för Genscript Biotech är för närvarande 8,99. P/S-talet jämför börsvärdet med den årliga omsättningen och fungerar som ett värderingsmått för Genscript Biotech-aktien.

Eulerpool Quality Score för Genscript Biotech är 5/10.

ISIN för Genscript Biotech är KYG3825B1059. ISIN (International Securities Identification Number) är en globalt unik identifierare för värdepapper.

WKN för Genscript Biotech är A2ACSB. WKN (Wertpapierkennnummer) är ett sexsiffrigt tyskt identifieringsnummer för värdepapper.

Tickern för Genscript Biotech är 1548.HK. Tickersymbolen används för att handla Genscript Biotech-aktier på börsen.

Fair ValueTerminal
3,44 USD
Över-/undervärderadTerminal
Rimligt värderad
Sektor
Industri
Livsvetenskapsverktyg och tjänster
Antal aktier
Anställda
Omsättning per anställd
241 511,70 USD
Intäktstillväxt Ø5 år
EBIT-tillväxt Ø5 år
Nettoinkomsttillväxt Ø5 år
Webbplats genscript.com
Land
Valuta
USD
Börsnoteringsdatum
30 dec. 2015
ISIN
KYG3825B1059
CUSIP
G3825B105
SEDOL
BD9Q2J2
Börsvärde
52-veckorsintervall
PEG
−0,06
P/E-tal
P/E 2026
948,00
P/E 2027
568,80
P/E 2028
21,73
P/E 2029
—
P/E 2030
—
P/S
P/S
8,99
EV/EBIT
31,12
P/B-tal
1,98
ROE (avkastning på eget kapital)
ROA (avkastning på tillgångar)
ROCE (avkastning på sysselsatt kapital)
ROIC (avkastning på investerat kapital)
−12,63 %
Utdelning
Direktavkastning
0,00 %
Beräknad direktavkastning
0,33 %
Utdelningskvot
10,11 %
Utdelningsvöxt Ø5år
—
Utdelningar per år
1
Utdelning betald sedan
0 år
Utdelning inte minskad sedan
0 år
Utdelning ökat sedan
0 år
Källskatt
10,00 %
Senast uppdaterad 22 nov. 2026 05:18

Genscript Biotech Ticker

FRANKFURT · G51.FHKEX · 1548.HKMÜNCHEN · G51.MUOTC · GNNSF

Genscript Biotech FIGI

1548:HK · BBG009XY51J1G51:GR · BBG00BV590J9G51:GF · BBG00BV590K7G51:GS · BBG00BV590N4G51:GM · BBG00BV590P2GNNSF:US · BBG00H8V6QP4GNNSF:PQ · BBG00H8V6R27GNNSF:UV · BBG00H8V6R361548:H2 · BBG00HMKD8T01548HKD:X2 · BBG00JZ5LCP11548HKD:XB · BBG00JZ5LCQ01548HKD:XH · BBG00JZ5LCS8